Study on the evaluation of anti-inflammation and anti-pigmentation effect of the P2 lotion after UV irradiation.

Not Applicable

• Conditions: Healthy adult

• Registration Number: JPRN-UMIN000046159
• Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-12-14
• Study Completion: 2021-12-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 24

Inclusion Criteria

Not provided

Exclusion Criteria

1)Subjects with photosensitive skin. 2)Subjects who have significant change of skin condition by menstrual cycle. 3)Subjects who take drugs that affect skin photosensitivity. 4)Subjects who have the factors on the target area which may affect this study. 5)Subjects who have got aesthetic medicine on the target area. 6)Subjects who continuously use skin care products or functional foods on the target area which had same or similar effect with the test sample. 7)Subjects who continuously use bath additive, excluding one who can stop using them during this study. 8)Subjects who continuously use moisturizer and/or body cream on the target area, excluding one who can stop using them during this study. 9)Subjects who continuously use drugs which have effect on pigmentation and/or melasma. 10)Subjects with atopic dermatitis, regardless of the area. 11)Subjects who have undergone special skincare treatment at the target area within 4 weeks or during this study. 12)Subjects who have changed and/or started using functional foods and/or sunscreen on the target area within 4 weeks. 13)Subjects who have or will be exposed to excessive UV beyond the daily life during this study. 14)Subjects who are night or shift workers. 15)Subjects who have treated or prevented their disease or need to be treatment in a clinic at the consent 16)Subjects who have serious diseases or medical history including glucose or lipid metabolisms, liver or kidney functions, cardiovascular, respiratory, endocrine or nervous systems. 17)Subjects with a history of alcohol and/or drug addiction. 18)Subjects who have a risk of allergy during this study. 19)Subjects who are pregnant, lactating or hoping to be pregnant during this study. 20)Subjects who participated in the similar study within 6 months. 21)Subjects who have participated or will participate in the other clinical study within 4 weeks. 22)Subjects who are judged as ineligible for participating in this study by the principle investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified